Can a 10-day antiviral course protect kidney transplant patients from severe COVID?
NCT ID NCT07197164
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the antiviral drug remdesivir for 10 days can prevent severe COVID-19 in kidney transplant recipients who have mild or no symptoms. About 15 adults will receive the drug starting just before their transplant. The goal is to see if this approach allows safe transplantation without delay and reduces the risk of serious illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hospital Universitari Germans Trias i Pujol
RECRUITINGBadalona, Barcelona, 08916, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••